vs
Side-by-side financial comparison of PROCORE TECHNOLOGIES, INC. (PCOR) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
PROCORE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($349.1M vs $196.9M, roughly 1.8× Pacira BioSciences, Inc.). On growth, PROCORE TECHNOLOGIES, INC. posted the faster year-over-year revenue change (15.6% vs 5.1%). PROCORE TECHNOLOGIES, INC. produced more free cash flow last quarter ($109.2M vs $43.5M). Over the past eight quarters, PROCORE TECHNOLOGIES, INC.'s revenue compounded faster (13.8% CAGR vs 8.5%).
Procore Technologies is an American construction management software as a service company founded in 2002, with headquarters in Carpinteria, California. Procore hosts a platform to connect those involved in the construction industry on a global platform. The software allows for the creation of simplified workflows and displays a consolidated view of construction products that includes the tracking of tasks, management of project workflows, and scheduling.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
PCOR vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $349.1M | $196.9M |
| Net Profit | $-37.6M | — |
| Gross Margin | 80.1% | 79.5% |
| Operating Margin | -12.3% | 1.2% |
| Net Margin | -10.8% | — |
| Revenue YoY | 15.6% | 5.1% |
| Net Profit YoY | 39.6% | — |
| EPS (diluted) | $-0.25 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $349.1M | $196.9M | ||
| Q3 25 | $338.9M | $179.5M | ||
| Q2 25 | $323.9M | $181.1M | ||
| Q1 25 | $310.6M | $168.9M | ||
| Q4 24 | $302.0M | $187.3M | ||
| Q3 24 | $295.9M | $168.6M | ||
| Q2 24 | $284.3M | $178.0M | ||
| Q1 24 | $269.4M | $167.1M |
| Q4 25 | $-37.6M | — | ||
| Q3 25 | $-9.1M | $5.4M | ||
| Q2 25 | $-21.1M | $-4.8M | ||
| Q1 25 | $-33.0M | $4.8M | ||
| Q4 24 | $-62.3M | — | ||
| Q3 24 | $-26.4M | $-143.5M | ||
| Q2 24 | $-6.3M | $18.9M | ||
| Q1 24 | $-11.0M | $9.0M |
| Q4 25 | 80.1% | 79.5% | ||
| Q3 25 | 79.7% | 80.9% | ||
| Q2 25 | 79.1% | 77.4% | ||
| Q1 25 | 79.1% | 79.7% | ||
| Q4 24 | 81.2% | 78.7% | ||
| Q3 24 | 81.4% | 76.9% | ||
| Q2 24 | 83.1% | 75.1% | ||
| Q1 24 | 83.0% | 71.6% |
| Q4 25 | -12.3% | 1.2% | ||
| Q3 25 | -4.4% | 3.5% | ||
| Q2 25 | -9.3% | 4.7% | ||
| Q1 25 | -11.7% | 1.2% | ||
| Q4 24 | -21.9% | 13.2% | ||
| Q3 24 | -12.3% | -82.8% | ||
| Q2 24 | -5.2% | 15.9% | ||
| Q1 24 | -7.0% | 7.9% |
| Q4 25 | -10.8% | — | ||
| Q3 25 | -2.7% | 3.0% | ||
| Q2 25 | -6.5% | -2.7% | ||
| Q1 25 | -10.6% | 2.8% | ||
| Q4 24 | -20.6% | — | ||
| Q3 24 | -8.9% | -85.1% | ||
| Q2 24 | -2.2% | 10.6% | ||
| Q1 24 | -4.1% | 5.4% |
| Q4 25 | $-0.25 | $0.05 | ||
| Q3 25 | $-0.06 | $0.12 | ||
| Q2 25 | $-0.14 | $-0.11 | ||
| Q1 25 | $-0.22 | $0.10 | ||
| Q4 24 | $-0.42 | $0.38 | ||
| Q3 24 | $-0.18 | $-3.11 | ||
| Q2 24 | $-0.04 | $0.39 | ||
| Q1 24 | $-0.08 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $768.5M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $1.3B | $693.1M |
| Total Assets | $2.2B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $768.5M | $238.4M | ||
| Q3 25 | $684.0M | $246.3M | ||
| Q2 25 | $620.9M | $445.9M | ||
| Q1 25 | $566.7M | $493.6M | ||
| Q4 24 | $775.4M | $484.6M | ||
| Q3 24 | $756.9M | $453.8M | ||
| Q2 24 | $735.4M | $404.2M | ||
| Q1 24 | $744.6M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.3B | $693.1M | ||
| Q3 25 | $1.2B | $727.2M | ||
| Q2 25 | $1.2B | $757.8M | ||
| Q1 25 | $1.2B | $798.5M | ||
| Q4 24 | $1.3B | $778.3M | ||
| Q3 24 | $1.3B | $749.6M | ||
| Q2 24 | $1.3B | $879.3M | ||
| Q1 24 | $1.2B | $892.2M |
| Q4 25 | $2.2B | $1.3B | ||
| Q3 25 | $2.1B | $1.3B | ||
| Q2 25 | $2.0B | $1.5B | ||
| Q1 25 | $1.9B | $1.6B | ||
| Q4 24 | $2.1B | $1.6B | ||
| Q3 24 | $2.0B | $1.5B | ||
| Q2 24 | $2.0B | $1.6B | ||
| Q1 24 | $1.9B | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $114.9M | $43.7M |
| Free Cash FlowOCF − Capex | $109.2M | $43.5M |
| FCF MarginFCF / Revenue | 31.3% | 22.1% |
| Capex IntensityCapex / Revenue | 1.6% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $282.2M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $114.9M | $43.7M | ||
| Q3 25 | $88.5M | $60.8M | ||
| Q2 25 | $30.8M | $12.0M | ||
| Q1 25 | $66.0M | $35.5M | ||
| Q4 24 | $29.1M | $33.1M | ||
| Q3 24 | $39.3M | $53.9M | ||
| Q2 24 | $58.7M | $53.2M | ||
| Q1 24 | $69.1M | $49.1M |
| Q4 25 | $109.2M | $43.5M | ||
| Q3 25 | $83.1M | $57.0M | ||
| Q2 25 | $27.9M | $9.3M | ||
| Q1 25 | $62.0M | $26.9M | ||
| Q4 24 | $17.4M | $31.0M | ||
| Q3 24 | $35.7M | $49.8M | ||
| Q2 24 | $56.8M | $51.6M | ||
| Q1 24 | $67.1M | $46.3M |
| Q4 25 | 31.3% | 22.1% | ||
| Q3 25 | 24.5% | 31.7% | ||
| Q2 25 | 8.6% | 5.1% | ||
| Q1 25 | 20.0% | 15.9% | ||
| Q4 24 | 5.8% | 16.6% | ||
| Q3 24 | 12.1% | 29.6% | ||
| Q2 24 | 20.0% | 29.0% | ||
| Q1 24 | 24.9% | 27.7% |
| Q4 25 | 1.6% | 0.1% | ||
| Q3 25 | 1.6% | 2.2% | ||
| Q2 25 | 0.9% | 1.5% | ||
| Q1 25 | 1.3% | 5.1% | ||
| Q4 24 | 3.9% | 1.1% | ||
| Q3 24 | 1.2% | 2.4% | ||
| Q2 24 | 0.7% | 0.9% | ||
| Q1 24 | 0.8% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× | ||
| Q1 24 | — | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
